Phathom Pharmaceuticals Inc (PHAT NASDAQ) stock market data APIs
$10.8899
0.64(5.9%)
as of September 16, 2025
Try our APIs with
free plan!
Phathom Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Prev. Close
10.8899
Open
11.5256
High
11.7023
Low
10.8944
52 wk Range
2.21-19.71
Market Cap
779 M
Shares Outstanding
70 944 K
Revenue
114 M
EPS
-0.79
Beta
0.443
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Phathom Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Phathom Pharmaceuticals Inc data using free add-ons & libraries
Get Phathom Pharmaceuticals Inc Fundamental Data
Phathom Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 114 M
- EBITDA: -268 266 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.91
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Phathom Pharmaceuticals Inc News
New
How The Pieces Add Up: FTKI Headed For $21
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, an...
Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing
FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed...
Phathom projects $165M–$175M 2025 revenue as GI sales focus accelerates VOQUEZNA growth
Earnings Call Insights: Phathom Pharmaceuticals (PHAT) Q2 2025 MANAGEMENT VIEW * Steven L. Basta, CEO, indicated that the quarter marked "a meaningful inflection point for Phathom" as the company ...
Phathom Pharmaceuticals (NASDAQ:PHAT) Surpasses Q2 Estimates with Strong VOQUEZNA Growth, Shares Jump 6% in Premarket
PHATHOM PHARMACEUTICALS (NASDAQ:PHAT) BEATS Q2 REVENUE AND EPS ESTIMATES, SHARES RISE IN PREMARKET Phathom Pharmaceuticals (NASDAQ:PHAT [https://www.chartmill.com/stock/quote/PHAT]) reported second-q...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
